Effect of mirasol pathogen reduction technology system on immunomodulatory molecules of apheresis platelets

被引:2
作者
Valsami, S. [1 ]
Grouzi, E. [2 ]
Mochandreou, D. [2 ]
Pouliakis, A. [3 ]
Piroula-Godoy, M. [4 ]
Kokori, S. [5 ]
Pittaras, T. [1 ]
Raikou, A. [2 ]
Politou, M. [1 ,4 ]
机构
[1] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Hematol Lab Blood Bank, Athens, Greece
[2] Agios Savvas Reg Canc Hosp, Dept Transfus Serv & Clin Hemostasis, Athens, Greece
[3] Univ Athens, ATTIKON Univ Hosp, Dept Cytopathol, Athens, Greece
[4] Natl & Kapodistrian Univ Athens, Masters Sci Programme Thrombosis Haemorrhage Trans, Athens, Greece
[5] Natl & Kapodistrian Athens, Attikon Univ Hosp, Lab Haematol & Blood Bank Unit, Athens, Greece
关键词
MIRASOL; Pathogen reduction tchnology; LD62P; RANTES; D" OL; PsateIet; Etood; BUFFY COAT PLATELETS; ADDITIVE SOLUTION; CYTOKINE ACCUMULATION; BLOOD COMPONENTS; QUALITY; RIBOFLAVIN; CD40; TRANSFUSION; ACTIVATION; LIGHT;
D O I
10.1016/j.transci.2022.103523
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pa iota hogen inactivation for platelets ry wbcflavin system (MIRASOL) efflciently rea::ce,. t center dot anafusion related pattioaen transmission. However little is knonn about its impact on platelets' immunomodulatory biochemical profile. Vve aimed ,cas to assess the euects of MIRASOL treatment on platelet guality parameters and inununomodulatmy molecules CD62P, RANTES, and CD4011 in Single Donor :`latelets (SDPs) resttspended in plasina (SDP-P) or T-PAS and additive solution (SDP-A). Twenty nine SDPs (15 SDP-P and 14 SDP-A) ,vere included in the study. Samples were collected before, after MIRASOL treatment and just before transfusion. P-selectin (CD62P), RANTES, and CD40L were tested by A:LISA. Platelet prodttcts guality assays were also perfonned. Platelet count/unit decreased after Mirasol treatment by 13 %. The pH of all units decreased over the 5-day storage period but remained above expected limits and the swirlinb test was positive throughout storage. Pselectin levels were not different between the three different time points in both SDPs-P and SDPs-A while RANTES levels were found to differ statistically significantly at the three different time points in all units and in the SPD-A subgroup. CD40L levels in all SDP products increased slightly during storage but this was not statistically significant. CDb2P, RANTES, and CD40L in all time points were elevated in SDPs-A compared to SDPs-P but not at a statistically significant level. [n condusion MIRASOL treatment apart from RANTES increase does not seem to substantially affect platelets associated other cytokines and immtmomodulatmy molecules namely Pselectin and sCD40L which are implicated in immune transfusion reactions.
引用
收藏
页数:5
相关论文
共 30 条
  • [21] Implementation strategy for complete pathogen reduction technology treated apheresis platelet inventory
    Shu, Elaine
    Batilo, Concepcion Dela Cruz
    Sussmann, Harry
    Owen, Bethany
    Belanger, Geoffrey A.
    Pandey, Suchitra
    Pham, Tho D.
    TRANSFUSION, 2022, 62 (10) : 2108 - 2116
  • [22] Effect of concurrent pathogen reduction (amotosalen/UVA) and gamma/x-ray irradiation on biochemical characteristics of apheresis platelets in additive solution
    Khoshi, M. Reza
    Skripchenko, Andrey
    Seifu, Robel
    Byrne, Karen
    West-Mitchell, K.
    Conry-Cantilena, Cathy
    Villa, Carlos H.
    Simak, Jan
    Vostal, Jaroslav G.
    TRANSFUSION, 2024, : 10 - 16
  • [23] Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma
    Kwon, S. Y.
    Kim, I. S.
    Bae, J. E.
    Kang, J. W.
    Cho, Y. J.
    Cho, N. S.
    Lee, S. W.
    VOX SANGUINIS, 2014, 107 (03) : 254 - 260
  • [24] Quantifying the impact of a novel virus on the economic value of pathogen reduction technology for platelets
    Irving, Adam
    Simmonds, Peter
    Irving, William
    Thomas, Stephen
    Neuberger, James
    TRANSFUSION, 2025, 65 (02) : 310 - 317
  • [25] Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products
    Li, J
    de Korte, D
    Woolum, MD
    Ruane, PH
    Keil, SD
    Lockerbie, O
    McLean, R
    Goodrich, RP
    VOX SANGUINIS, 2004, 87 (02) : 82 - 90
  • [26] Cost-effectiveness of pathogen reduction technology for plasma and platelets in Quebec: A focus on potential emerging pathogens
    Gregoire, Yves
    Delage, Gilles
    Custer, Brian
    Rochette, Samuel
    Renaud, Christian
    Lewin, Antoine
    Germain, Marc
    TRANSFUSION, 2022, 62 (06) : 1208 - 1217
  • [27] Mirasol Pathogen Reduction Technology® treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components
    Silliman, C. C.
    Khan, S. Y.
    Ball, J. Bradley
    Kelher, M. R.
    Marschner, S.
    VOX SANGUINIS, 2010, 98 (04) : 525 - 530
  • [28] Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction
    Picker, S. M.
    Oustianskaia, L.
    Schneider, V.
    Gathof, B. S.
    VOX SANGUINIS, 2009, 97 (01) : 26 - 33
  • [29] In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system
    van der Meer, P. F.
    Kerkhoffs, J.-L.
    Curvers, J.
    Scharenberg, J.
    de Korte, D.
    Brand, A.
    de Wildt-Eggen, J.
    VOX SANGUINIS, 2010, 98 (04) : 517 - 524
  • [30] Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system
    Owada, Takashi
    Kaneko, Moe
    Matsumoto, Chieko
    Sobata, Rieko
    Igarashi, Masashi
    Suzuki, Ko
    Matsubayashi, Keiji
    Mio, Kazuhiro
    Uchida, Shigeharu
    Satake, Masahiro
    Tadokoro, Kenji
    TRANSFUSION, 2014, 54 (11) : 2820 - 2827